

## Management of recurrence after local treatment

Poster Session 72

Monday, 27 March  
14:00 - 15:30

**Location:** Room Paris, North Hall (Level 1)

**Chairs:** S. Joniau, Leuven (BE)  
N. Mottet, Saint-Étienne (FR)  
K. Touijer, New York (US)

**Aims and objectives of this session**

To evaluate the imaging and markers for recurrence and adjuvant or salvage treatments results.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

950 **External validation of a TCP model predicting PSA relapse after post-prostatectomy radiotherapy**  
By: Broggi S.<sup>2</sup>, Galla A.<sup>3</sup>, Saracino B.<sup>4</sup>, Faiella A.<sup>4</sup>, Fossati N.<sup>5</sup>, Gabriele D.<sup>3</sup>, Maggio A.<sup>3</sup>, Sanguineti G.<sup>4</sup>, Di Muzio N.<sup>1</sup>, Briganti A.<sup>1</sup>, Cozzarini C.<sup>1</sup>, Fiorino C.<sup>2</sup>

**Institutes:**<sup>1</sup>San Raffaele Scientific Institute, Dept. of Radiotherapy, Milan, Italy, <sup>2</sup>San Raffaele Scientific Institute, Dept. of Medical Physics, Milan, Italy, <sup>3</sup>Candiolo Cancer Institute - FPO, IRCCS, Dept. of Radiotherapy, Candiolo, Italy, <sup>4</sup>Regina Elena National Cancer Institute, Dept. of Radiotherapy, Rome, Italy, <sup>5</sup>San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

951 **Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model**

By: Dalela D.<sup>1</sup>, Santiago-Jimenez M.<sup>2</sup>, Yousefi K.<sup>2</sup>, Karnes J.<sup>3</sup>, Ross A.<sup>4</sup>, Den R.<sup>5</sup>, Freedland S.<sup>6</sup>, Schaeffer E.<sup>7</sup>, Dicker A.<sup>5</sup>, Menon M.<sup>1</sup>, Briganti A.<sup>8</sup>, Abdollah F.<sup>1</sup>

**Institutes:**<sup>1</sup>Henry Ford Health System, Vattikuti Urology Institute, Detroit, United States of America, <sup>2</sup>GenomeDx Biosciences, GenomeDx Biosciences, Vancouver, Canada, <sup>3</sup>Mayo Clinic, Dept. of Urology, Rochester, United States of America, <sup>4</sup>Johns Hopkins Hospital, James Buchanan Brady Urological Institute, Baltimore, United States of America, <sup>5</sup>Sidney Kimmel Cancer Center, Thomas Jefferson University, Dept. of Radiation Oncology, Philadelphia, United States of America, <sup>6</sup>Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Dept. of Surgery, Division of Urology, Los Angeles, United States of America, <sup>7</sup>Northwestern University, Feinberg School of Medicine, Dept. of Urology, Chicago, United States of America, <sup>8</sup>Vita Salute San Raffaele Hospital, Dept. of Urology, Milan, Italy

952 **Natural history of patients treated with salvage radiation therapy for rising PSA after radical prostatectomy: A long-term survival analysis**

By: Briganti A.<sup>1</sup>, Fossati N.<sup>1</sup>, Karnes J.<sup>2</sup>, Boorjian S.<sup>2</sup>, Colicchia M.<sup>2</sup>, Bossi A.<sup>3</sup>, Cozzarini C.<sup>4</sup>, Fiorino C.<sup>4</sup>, Noris Chiorda B.<sup>4</sup>, Dell'Oglio P.<sup>1</sup>, Gandaglia G.<sup>1</sup>, Wiegel T.<sup>5</sup>, Shariat S.<sup>6</sup>, Goldner G.<sup>7</sup>, Joniau S.<sup>8</sup>, Battaglia A.<sup>8</sup>, Haustermans K.<sup>9</sup>, De Meerleer G.<sup>9</sup>, Fonteyne V.<sup>10</sup>, Ost P.<sup>10</sup>, Van Poppel H.<sup>5</sup>, Montorsi F.<sup>1</sup>

**Institutes:**<sup>1</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>2</sup>Mayo Clinic, Dept. of Urology, Rochester, United States of America, <sup>3</sup>Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, <sup>4</sup>Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, <sup>5</sup>University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, <sup>6</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria, <sup>7</sup>Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, <sup>8</sup>University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, <sup>9</sup>University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, <sup>10</sup>Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

- \*953 **Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: Results from a large, multi-institutional analysis**  
**By:** Suardi N.<sup>1</sup>, Briganti A.<sup>1</sup>, Fossati N.<sup>1</sup>, Dell'Oglio P.<sup>1</sup>, Gandaglia G.<sup>1</sup>, Colicchia M.<sup>2</sup>, Karnes J.R.<sup>2</sup>, Haidl F.<sup>8</sup>, Pfister D.<sup>8</sup>, Porres D.<sup>8</sup>, Heidenreich A.<sup>8</sup>, Gratzke C.<sup>7</sup>, Herlemann A.<sup>7</sup>, Stief C.<sup>7</sup>, Battaglia A.<sup>5</sup>, Everaerts W.<sup>5</sup>, Joniau S.<sup>5</sup>, Van Poppel H.<sup>5</sup>, Aksenov A.<sup>4</sup>, Osmonov D.K.<sup>4</sup>, Jünemann K.P.<sup>9</sup>, Abreu A.D.L.<sup>3</sup>, Almeida F.<sup>3</sup>, Fay C.<sup>6</sup>, Gill I.<sup>6</sup>, Mottrie A.M.<sup>10</sup>, Montorsi F.<sup>1</sup>  
**Institutes:**<sup>1</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>2</sup>Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, <sup>3</sup>Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, <sup>4</sup>Department of Urology and Pediatric Urology, University Hospital Schleswig Holstein, Campus Kiel, Dept. of Urology, Kiel, Germany, <sup>5</sup>University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, <sup>6</sup>Keck School of Medicine, University of Southern California, USC Institute of Urology, Catherine & Joseph Aresty Department of Urology, Los Angeles, California, United States of America, <sup>7</sup>Ludwig-Maximilians-University, Dept. of Urology, Munich, Germany, <sup>8</sup>University of Cologne, Dept. of Urology, Cologne, Germany, <sup>9</sup>University Hospital Schleswig Holstein, Campus Kiel, Dept. of Urology and Pediatric Urology, Kiel, Germany, <sup>10</sup>OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium
- 954 **Selection criteria for surveillance in patients with biochemical recurrence after radical prostatectomy**  
**By:** Mikami H., Numao N., Yamamoto S., Hagiwara K., Uehara S., Takeda H., Inoue T., Ogawa M., Yuasa T., Masuda H., Fukui I., Yonese J.  
**Institutes:**Cancer Institute Hospital, Japanese Foundation for Cancer Research, Dept. of Urology, Koto-Ku, Japan
- 955 **Adjuvant versus early salvage radiation therapy in node positive prostate cancer patients: A long-term survival analysis**  
**By:** Fossati N.<sup>1</sup>, Karnes R.J.<sup>2</sup>, Boorjian S.<sup>2</sup>, Colicchia M.<sup>2</sup>, Bossi A.<sup>3</sup>, Cozzarini C.<sup>4</sup>, Fiorino C.<sup>4</sup>, Chiorda B.N.<sup>4</sup>, Gandaglia G.<sup>1</sup>, Dell'Oglio P.<sup>1</sup>, Wiegel T.<sup>5</sup>, Shariat S.<sup>6</sup>, Goldner G.<sup>7</sup>, Joniau S.<sup>8</sup>, Battaglia A.<sup>8</sup>, Haustermans K.<sup>9</sup>, De Meerleer G.<sup>9</sup>, Fonteyne V.<sup>10</sup>, Ost P.<sup>10</sup>, Van Poppel H.<sup>5</sup>, Montorsi F.<sup>1</sup>, Briganti A.<sup>1</sup>  
**Institutes:**<sup>1</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>2</sup>Mayo Clinic, Dept. of Urology, Rochester, United States of America, <sup>3</sup>Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France, <sup>4</sup>Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, <sup>5</sup>University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, <sup>6</sup>Medical University of Vienna, Dept. of Urology, Vienna, Austria, <sup>7</sup>Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, <sup>8</sup>University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, <sup>9</sup>University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, <sup>10</sup>Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium
- 956 **Salvage external beam radiation therapy (EBRT) for local recurrence after high intensity focused ultrasound (HIFU) failure versus salvage HIFU for local recurrence after EBRT failure: A long term analysis**  
**By:** Lee J-W.<sup>1</sup>, Crouzet S.<sup>1</sup>, Soria J.<sup>1</sup>, Chapelon A.<sup>2</sup>, Chapelon J.Y.<sup>2</sup>, Melodelima C.<sup>3</sup>, Gal J.<sup>4</sup>, Pasticier G.<sup>5</sup>, Mege-Lechevallier F.<sup>6</sup>, Rouvière O.<sup>7</sup>, Gelet A.<sup>1</sup>  
**Institutes:**<sup>1</sup>Hospices Civils De Lyon, Dept. of Urology and Transplantation, Lyon, France, <sup>2</sup>Inserm, U1032, LabTau, Lyon, France, <sup>3</sup>Laboratoire d'Ecologie Alpine, Grenoble, France, <sup>4</sup>Centre Antoine Lacassagne, Dept. of Biostatistics, Nice, France, <sup>5</sup>Pellegrin Hospital, Dept. of Urology and Transplantation, Bordeaux, France, <sup>6</sup>Edouard Herriot Hospital, Dept. of Pathology, Lyon, France, <sup>7</sup>Edouard Herriot Hospital, Dept. of Radiology, Lyon, France
- 957 **Predictive factors of positive 68Ga-PSMA PET/CT in patients with PSA recurrence following radical prostatectomy**  
**By:** Tosco L.<sup>1</sup>, Joniau S.<sup>1</sup>, Witters M.<sup>1</sup>, Battaglia A.<sup>1</sup>, Cromphout L.<sup>2</sup>, Goffin K.<sup>2</sup>, Gheysens O.<sup>2</sup>, Deroose C.<sup>2</sup>, Oyen R.<sup>2</sup>, Van Laere K.<sup>2</sup>  
**Institutes:**<sup>1</sup>Uz Leuven - Campus Gasthuisberg, Dept. of Urology, Leuven, Belgium, <sup>2</sup>Uz Leuven - Campus Gasthuisberg, Dept. of Nuclear Imaging, Leuven, Belgium

- 958 **Clinical impact of 68Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: Preliminary analysis of a multidisciplinary approach**  
**By:** [Albisinni S.](#)<sup>1</sup>, Artigas C.<sup>2</sup>, Aoun F.<sup>1</sup>, Biau I.<sup>1</sup>, Gil T.<sup>3</sup>, Hawaux E.<sup>1</sup>, Limani K.<sup>1</sup>, Otte F.X.<sup>4</sup>, Peltier A.<sup>1</sup>, Sideris S.<sup>3</sup>, Sirtaine N.<sup>5</sup>, Flamen P.<sup>2</sup>, Van Velthoven R.<sup>1</sup>  
**Institutes:**<sup>1</sup>Institut Jules Bordet, Dept. of Urology, Brussels, Belgium, <sup>2</sup>Institut Jules Bordet, Dept. of Nuclear Medicine, Brussels, Belgium, <sup>3</sup>Institut Jules Bordet, Dept. of Oncology, Brussels, Belgium, <sup>4</sup>Institut Jules Bordet, Dept. of Radiotherapy, Brussels, Belgium, <sup>5</sup>Institut Jules Bordet, Dept. of Pathology, Brussels, Belgium
- 959 **68Ga-PSMA PET/CT improves biochemical response after salvage lymph node dissection for nodal recurrence in prostate cancer patients**  
**By:** [Herlemann A.](#)<sup>1</sup>, Kretschmer A.<sup>1</sup>, Buchner A.<sup>1</sup>, Karl A.<sup>1</sup>, Tritschler S.<sup>1</sup>, El-Malazi L.<sup>1</sup>, Wenter V.<sup>2</sup>, Ilhan H.<sup>2</sup>, Bartenstein P.<sup>2</sup>, Stief C.<sup>1</sup>, Gratzke C.<sup>1</sup>  
**Institutes:**<sup>1</sup>Ludwig-Maximilians-University Munich, Dept. of Urology, Munich, Germany, <sup>2</sup>Ludwig-Maximilians-University Munich, Dept. of Nuclear Medicine, Munich, Germany
- 960 **The comparison of prognoses between radiotherapy and radical prostatectomy in patients with high risk localized or locally advanced prostate cancer treated with neoadjuvant hormonal therapy**  
**By:** Joung J.Y.<sup>1</sup>, Kim S.H.<sup>1</sup>, Seo H.K.<sup>1</sup>, [Chung J.](#)<sup>1</sup>, Cho K.H.<sup>2</sup>, Park W.S.<sup>3</sup>, Lee K.H.<sup>1</sup>  
**Institutes:**<sup>1</sup>National Cancer Center, Dept. of Genitourinary Cancer Branch, Goyang, South Korea, <sup>2</sup>National Cancer Center, Proton Therapy Center, Dept. of Radiation Oncology, Goyang, South Korea, <sup>3</sup>National Cancer Center, Dept. of Pathology, Goyang, South Korea
- 962 **Stereotactic radiotherapy for bone and nodal oligometastases: Patterns of relapse in a prospective clinical trial**  
**By:** Siva S.<sup>2</sup>, Udovicich C.<sup>1</sup>, Shaw M.<sup>2</sup>, Violet J.<sup>2</sup>, Chander S.<sup>2</sup>, Bressel M.<sup>3</sup>, Goad J.<sup>1</sup>, Lawrentschuck N.<sup>1</sup>, Foroudi F.<sup>1</sup>, [Murphy D.](#)<sup>1</sup>  
**Institutes:**<sup>1</sup>Peter Maccallum Cancer Centre, Dept. of Urology, Melbourne, Australia, <sup>2</sup>Peter Maccallum Cancer Centre, Dept. of Radiation Oncology, Melbourne, Australia, <sup>3</sup>Peter Maccallum Cancer Centre, Dept. of Biostatistics and Clinical Trials, Melbourne, Australia
- 963 **Assessing the risk of early and late toxicity of post-prostatectomy radiation therapy: A long-term multi-institutional analysis**  
**By:** [Briganti A.](#)<sup>1</sup>, Fossati N.<sup>5</sup>, Karnes J.<sup>2</sup>, Boorjian S.<sup>2</sup>, Colicchia M.<sup>2</sup>, Bossi A.<sup>3</sup>, Cozzarini C.<sup>4</sup>, Fiorino C.<sup>4</sup>, Noris Chiorda B.<sup>4</sup>, Dell'Oglio P.<sup>5</sup>, Gandaglia G.<sup>5</sup>, Wiegel T.<sup>6</sup>, Shariat S.<sup>7</sup>, Goldner G.<sup>8</sup>, Joniau S.<sup>9</sup>, Battaglia A.<sup>9</sup>, Haustermans K.<sup>10</sup>, De Meerleer G.<sup>10</sup>, Fonteyne V.<sup>11</sup>, Ost P.<sup>11</sup>, Van Poppel H.<sup>9</sup>, Montorsi F.<sup>5</sup>  
**Institutes:**<sup>1</sup>Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, <sup>2</sup>Mayo Clinic, Dept. of Urology, Rochester, United States of America, <sup>3</sup>Gustave Roussy Institute, Dept. of Urology, Villejuif, France, <sup>4</sup>Vita-Salute University San Raffaele, Dept. of Radiotherapy, Milan, Italy, <sup>5</sup>Vita-Salute University San Raffaele, Dept. of Oncology and Urology, Milan, Italy, <sup>6</sup>University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, <sup>7</sup>Medical University of Vienna, Dept. of Oncology and Urology, Vienna, Austria, <sup>8</sup>Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, <sup>9</sup>University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, <sup>10</sup>University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, <sup>11</sup>Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium